Sanofi is investing €170 million to expand a vaccine manufacturing site in Val de Reuil, France. The new facility will allow Sanofi Pasteur, the Vaccines unit of Sanofi, to expand the global supply of its new quadrivalent influenza vaccine, VaxigripTetra. The new vaccine contains two A strains and two B strains of influenza virus, as per World Health Organization recommendation. Sanofi plans to complete the expansion by 2021, and begin producing vaccines at this site in 2022.

“This project brings together the expertise of our people with our leading industrial know-how and illustrates our commitment to manufacturing excellence solutions,” said Philippe Luscan, Executive Vice President, Global Industrial Affairs, Sanofi. “Our investment underlines Sanofi’s intent to strengthen our industrial capacities in France as a major centre of influenza vaccines production for worldwide markets.”

This investment is one of several major investments Sanofi has made recently to improve and expand its vaccine production capacities across France, the U.S. and Mexico.